Correlation of serum and ascitic IL-12 levels with second-look laparotomy results and disease progression in advanced epithelial ovarian cancer patients

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 83-86

  Bozkurt, N ^a,c   Yuce, K ^a   Basaran, M ^a   Gariboglu, S ^a   Kose, F ^b   Ayhan, A ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b SSK Ankara Maternity Hospital   (Turkey)

^c NONE   (Turkey)

Author keywords

Ascites; Interleukin 12; Ovarian cancer; Prognosis; Serum

Indexed keywords

INTERLEUKIN 12;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CARCINOMA; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-12; LAPAROTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; SECOND-LOOK SURGERY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33645351160     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00464.x     Document Type: Article

References (27)

1. Nastala CL Edington HD McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994 153 1697 706.
2. Trinchieri G Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994 15 460 3.
3. Gately MK Wolitzky AG Quinn PM Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992 143 127 42.
4. Kawamura T Takeda K Mendiratta SK et al. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 1998 160 16 9.
5. Fujiwara H Hamaoka T. The anti-tumor effects of IL-12 involve enhanced IFN-gamma production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-gamma production. Leukemia 1997 11 Suppl. 2 S570 1.
6. Lissoni P Mengo S Mandala M et al. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy. J Biol Regul Homeost Agents 1998 12 38 41.
7. Kobayashi M Fitz L Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989 170 827 45.
8. Podlaski FJ Nanduri VB Hulmes JD et al. Molecular characterization of interleukin 12. Arch Biochem Biophys 1992 294 230 7.
9. Soiffer RJ Robertson MJ Murray C Cochran K Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993 82 2790 6.
10. Banks RE Patel PM Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995 71 655 9.
11. Gately MK Renzetti LM Magram J et al. The interleukin-12/interleukin-12- receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998 16 495 521.
12. Brunda MJ Luistro L Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993 178 1223 30.
13. Zeimet AG Widschwendter M Knabbe C et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998 16 1861 8.
14. DeCesare SL Michelini-Norris B Blanchard DK et al. Interleukin-12- mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system. Gynecol Oncol 1995 57 86 95.
15. Benedet JL Bender H Jones H III. Ngan HY Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000 70 209 62.
16. Melero I Mazzolini G Narvaiza I Qian C Chen L Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 2001 22 113 5.
17. Voest EE Kenyon BM O'Reilly MS Truitt G D'Amato RJ Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995 87 581 6.
18. Angiolillo AL Sgadari C Tosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci 1996 795 158 67.
19. Koblish HK Hunter CA Wysocka M Trinchieri G Lee WM. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J Exp Med 1998 188 1603 10.
20. Kurzawa H Wysocka M Aruga E Chang AE Trinchieri G Lee WM. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res 1998 58 491 9.
21. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother 2001 55 111 6.
22. Lissoni P Rovelli F Pittalis S et al. Interleukin-12 in early or advanced cancer patients. Eur J Cancer 1997 33 1703 5.
23. Lissoni P Rovelli F Fumagalli L Mauri E Barni S Tancini G. Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observations. Int J Biol Markers 1997 12 125 7.
24. Marana HR Andrade JM Silva JS Natural killer cells and interleukin-12 in patients with advanced cervical cancer under neoadjuvant chemotherapy. Braz J Med Biol Res 1996 29 473 7.
25. Chiodoni C Stoppacciaro A Sangaletti S et al. Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. Eur J Immunol 2001 31 3101 10.
26. Colombo MP Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002 13 155 68.
27. Hurteau JA Blessing JA DeCesare SL Creasman WT. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2001 82 7 10.